pyridoxine has been researched along with Colorectal Neoplasms in 7 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Colorectal cancer patients scheduled to receive capecitabine chemotherapy as adjuvant therapy were randomly assigned to receive TJ-28 (7500 mg/day) or oral pyridoxine (60 mg/day)." | 9.34 | The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). ( Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K, 2020) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 9.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "Obesity increases the colorectal cancer risk, in part by elevating colonic proinflammatory cytokines." | 5.62 | Combined Supplementation with Vitamin B-6 and Curcumin is Superior to Either Agent Alone in Suppressing Obesity-Promoted Colorectal Tumorigenesis in Mice. ( Bronson, RT; Crott, JW; Koh, GY; Liang, X; Mason, JB; Roper, J; Ueland, PM; Wu, X; Yilmaz, ÖH, 2021) |
| " Colorectal cancer patients scheduled to receive capecitabine chemotherapy as adjuvant therapy were randomly assigned to receive TJ-28 (7500 mg/day) or oral pyridoxine (60 mg/day)." | 5.34 | The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). ( Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K, 2020) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 5.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily." | 5.16 | A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012) |
| "Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis." | 5.14 | Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010) |
| "In vitro simultaneous combination of OHP and pyridoxine was studied in 6 CRC cell lines (HT29, Widr, SW480, HCT116, H630 and SW1116), in an ovarian cancer cell line (A2780) and its cisplatin-resistant subline (ADDP) and in an oestrogen-dependent breast cancer cell line (MCF-7)." | 3.77 | Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. ( Ackland, SP; Garg, MB, 2011) |
| "Obesity increases the colorectal cancer risk, in part by elevating colonic proinflammatory cytokines." | 1.62 | Combined Supplementation with Vitamin B-6 and Curcumin is Superior to Either Agent Alone in Suppressing Obesity-Promoted Colorectal Tumorigenesis in Mice. ( Bronson, RT; Crott, JW; Koh, GY; Liang, X; Mason, JB; Roper, J; Ueland, PM; Wu, X; Yilmaz, ÖH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, X | 1 |
| Ueland, PM | 1 |
| Roper, J | 1 |
| Koh, GY | 1 |
| Liang, X | 1 |
| Crott, JW | 1 |
| Yilmaz, ÖH | 1 |
| Bronson, RT | 1 |
| Mason, JB | 1 |
| Watanabe, K | 2 |
| Ishibe, A | 1 |
| Watanabe, J | 2 |
| Ota, M | 2 |
| Fujii, S | 1 |
| Ichikawa, Y | 2 |
| Oba, MS | 1 |
| Endo, I | 2 |
| Machover, D | 1 |
| Almohamad, W | 1 |
| Castagné, V | 1 |
| Desterke, C | 1 |
| Gomez, L | 1 |
| Gaston-Mathé, Y | 1 |
| Boucheix, C | 1 |
| Goldschmidt, E | 1 |
| Tatsumi, K | 1 |
| Suwa, H | 1 |
| Osada, S | 1 |
| Tanaka, K | 1 |
| Shoichi, F | 1 |
| Kunisaki, C | 1 |
| Chalermchai, T | 1 |
| Tantiphlachiva, K | 1 |
| Suwanrusme, H | 1 |
| Voravud, N | 1 |
| Sriuranpong, V | 1 |
| Garg, MB | 1 |
| Ackland, SP | 1 |
| Corrie, PG | 1 |
| Bulusu, R | 1 |
| Wilson, CB | 1 |
| Armstrong, G | 1 |
| Bond, S | 1 |
| Hardy, R | 1 |
| Lao-Sirieix, S | 1 |
| Parashar, D | 1 |
| Ahmad, A | 1 |
| Daniel, F | 1 |
| Hill, M | 1 |
| Wilson, G | 1 |
| Blesing, C | 1 |
| Moody, AM | 1 |
| McAdam, K | 1 |
| Osborne, M | 1 |
4 trials available for pyridoxine and Colorectal Neoplasms
| Article | Year |
|---|---|
The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug The | 2020 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2014 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col | 2010 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas | 2012 |
3 other studies available for pyridoxine and Colorectal Neoplasms
| Article | Year |
|---|---|
Combined Supplementation with Vitamin B-6 and Curcumin is Superior to Either Agent Alone in Suppressing Obesity-Promoted Colorectal Tumorigenesis in Mice.
Topics: Animals; Carcinogenesis; Colorectal Neoplasms; Curcumin; Diet, High-Fat; Dietary Supplements; Male; | 2021 |
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2021 |
Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Cos | 2011 |